Actively Recruiting
Randomized Trial Comparing Aspirin and Rivaroxaban for Blood Clot Prevention in Newly Diagnosed Multiple Myeloma Patients Receiving Immunomodulatory Therapy
Led by Chen Lijuan · Updated on 2026-10-30
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating aspirin versus rivaroxaban to prevent blood clots in patients newly diagnosed with multiple myeloma who are receiving immunomodulatory drug-based therapy. This trial aims to find out if rivaroxaban lowers the chance of venous thromboembolism VTE compared to aspirin and to compare their safety profiles, especially regarding bleeding events. The study is an open-label, randomized trial conducted at a single center following international guidelines for good clinical practice. Participants will be randomly assigned to receive either aspirin 100 mg daily or rivaroxaban 10 mg daily, taken orally for at least 6 months during their immunomodulatory drug treatment. No other blood-thinning agents are allowed during this period. The study assesses the occurrence of VTE events as the primary outcome and also evaluates adverse events and bleeding episodes. Risk assessment scores IMPEDE VTE and SAVED will be used to predict VTE risk. Throughout the study, participants will be followed for 12 months with evaluations every 3 months or when clinically needed to detect VTE. Safety monitoring includes recording adverse and serious adverse events. Researchers will collect data to compare the treatments effectiveness and risks, aiming to improve future thromboprophylaxis strategies for this patient group.
CONDITIONS
Brief Title
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Research Team
L
Lijuan Chen
Q
Qinglin Shi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here